Chemistry:Ribonucleotide reductase inhibitor

From HandWiki
Revision as of 20:14, 5 February 2024 by Ohm (talk | contribs) (correction)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides (building blocks of DNA). Examples include:

See also

References

  1. "Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd)". Biochem. Biophys. Res. Commun. 379 (3): 775–9. January 2009. doi:10.1016/j.bbrc.2008.12.128. PMID 19121624. 
  2. "Short-term treatment with novel ribonucleotide reductase inhibitors Trimidox and Didox reverses late-stage murine retrovirus-induced lymphoproliferative disease with less bone marrow toxicity than hydroxyurea". Antivir. Chem. Chemother. 13 (5): 305–14. September 2002. doi:10.1177/095632020201300506. PMID 12630679. 
  3. "Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies". Expert Rev Anticancer Ther 2 (4): 437–48. August 2002. doi:10.1586/14737140.2.4.437. PMID 12647987. 
  4. Bernstein LR (1998). "Mechanisms of therapeutic activity for gallium". Pharmacol. Rev. 50 (4): 665–682. PMID 9860806. http://pharmrev.aspetjournals.org/cgi/reprint/50/4/665.pdf. 
  5. Bitonti, A. J.; Dumont, J. A.; Bush, T. L.; Cashman, E. A.; Cross-Doersen, D. E.; Wright, P. S.; Matthews, D. P.; McCarthy, J. R. et al. (15 March 1994). "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase". Cancer Research 54 (6): 1485–1490. PMID 8137252. https://pubmed.ncbi.nlm.nih.gov/8137252/. 
  6. "Tezacitabine monohydrate". https://pubchem.ncbi.nlm.nih.gov/compound/9925544. 

External links

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".